Answers are grounded in this paper and cite their sources.
To narratively and comprehensively synthesize the bidirectional mechanisms of glioma-associated cerebral infarction, examine how anti-glioma therapies alter the coagulation system, and clarify the implications for thrombotic risk management and integrated treatment. Peer-reviewed literature retrieved from PubMed and Web of Science (inception to August 2026) was synthesized across the procoagulant mechanisms of gliomas, the reverse pro-tumor effects of the post-infarction microenvironment, and the coagulation-related effects of the major anti-glioma drug classes and their interaction with anticoagulation. Glioma cells drive systemic hypercoagulability through tissue factor (TF), podoplanin (PDPN), and neutrophil extracellular traps (NETs). Thrombin enriched in the infarcted niche activates protease-activated receptors (PARs) on glioma cells and, together with inflammatory signaling and stabilized hypoxia-inducible factor-1α (HIF-1α), favors proliferation and invasion, whereas links to stem-cell maintenance and temozolomide resistance remain extrapolated; direct evidence in the reverse, infarction-to-glioma direction is limited. Alkylating agents, anti-angiogenic drugs, and immune checkpoint inhibitors differ in how they shift thrombosis and bleeding risk, and combining them with anticoagulants requires context-specific judgment. The glioma–coagulation–infarction axis offers a framework for integrating molecular mechanisms with bedside decisions, and supports individualized, platelet- and therapy-stratified anticoagulation within coordinated neuro-oncological management.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: